Abstract

Varicella-zoster virus (VZV) causes both varicella and herpes zoster.1,2 In 1995 a varicella vaccine was licensed in the USA and was incorporated into the routine vaccination programme for children; a decline of varicella among children and adults, and a reduction in associated hospitalisation, complications and mortality, has resulted.2 In the UK, a policy of targeted vaccination of at-risk groups has been in place since the vaccine was introduced.3 Here we review the evidence for the different approaches to VZV vaccination policy.